143 related articles for article (PubMed ID: 30047799)
1. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C.
Adinolfi LE; Rinaldi L; Marrone A; Giordano M
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):595-597. PubMed ID: 30047799
[No Abstract] [Full Text] [Related]
2. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
[TBL] [Abstract][Full Text] [Related]
3. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
4. Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype.
Lee SW; Yang SS; Lee TY; Yeh HZ; Lu IT; Chang CS
J Gastrointestin Liver Dis; 2017 Jun; 26(2):205-206. PubMed ID: 28617895
[No Abstract] [Full Text] [Related]
5. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals.
Yoh K; Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Hasegawa K; Nakano C; Nishimura T; Aizawa N; Sakai Y; Ikeda N; Takashima T; Takata R; Iijima H; Nishiguchi S
Nutrients; 2017 Oct; 9(10):. PubMed ID: 29057827
[TBL] [Abstract][Full Text] [Related]
6. Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.
Vitrone M; Andini R; Mattucci I; Maiello C; Atripaldi L; Durante-Mangoni E; Zampino R
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29139181
[TBL] [Abstract][Full Text] [Related]
7. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
8. Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study).
Boraie MB; Elnaggar YA; Ahmed MO; Mahmoud AM
Diabetes Metab Syndr; 2019; 13(4):2641-2646. PubMed ID: 31405688
[TBL] [Abstract][Full Text] [Related]
9. The remaining challenges of HCV treatment in the direct-acting antivirals era.
Kim BK; Ahn SH
J Gastroenterol Hepatol; 2019 Nov; 34(11):1891-1892. PubMed ID: 31724229
[No Abstract] [Full Text] [Related]
10. Hepatitis C Virus and Antiviral Drug Resistance.
Kim S; Han KH; Ahn SH
Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
[TBL] [Abstract][Full Text] [Related]
11. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
12. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
[TBL] [Abstract][Full Text] [Related]
13. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C.
Li J; Gordon SC; Rupp LB; Zhang T; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M;
Liver Int; 2019 Jun; 39(6):1027-1032. PubMed ID: 30570808
[TBL] [Abstract][Full Text] [Related]
14. HCV treatment with direct acting antivirals improves the insulin sensitivity.
Alsebaey A; Elhelbawy M; Abdel-Razek W; Hashim M; Elshenawy H; Waked I
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):749-754. PubMed ID: 31393188
[No Abstract] [Full Text] [Related]
15. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
Sherigar JM; Gayam V; Khan A; Mukhtar O; Arefiev Y; Khalid M; Siddiqui I; Rangaraju AM; Budhathoki N; Mansour M; Guss D; Mohanty SR
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):767-776. PubMed ID: 28346233
[TBL] [Abstract][Full Text] [Related]
17. Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents.
Suraweera D; Saab EG; Tong MJ; Saab S
Exp Clin Transplant; 2016 Jun; 14(3):243-51. PubMed ID: 27221717
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.
Pol S; Marion O; Vallet-Pichard A; Meritet JF; Sauné K; Alric L; Kamar N
Transpl Infect Dis; 2018 Jun; 20(3):e12864. PubMed ID: 29512231
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting.
Cooper C
Clin Infect Dis; 2012 Aug; 55(3):418-25. PubMed ID: 22491342
[TBL] [Abstract][Full Text] [Related]
20. What does the pharmacological future of treating chronic hepatitis C look like?
Heil EL; Hynicka LM; Kottilil S; Tang L
Expert Rev Clin Pharmacol; 2015; 8(5):605-22. PubMed ID: 26289223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
